Evidence map›Paper›PMID 29739258›Full record

ArticleHuman & experimental toxicology2018

4-Methylpyrazole protects against acetaminophen hepatotoxicity in mice and in primary human hepatocytes.

J Y Akakpo, A Ramachandran, S E Kandel, H M Ni, S C Kumer, B H Rumack, H Jaeschke

Abstract read
In one paragraph

Article in Human & experimental toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 111 citations in OpenAlex.

  1. Trial
  2. The Effect of 4-Methylpyrazole on Oxidative Metabolism of Acetaminophen in Human Volunteers.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2020
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Are New Approach Methodologies (NAMs) the Holy Grail of toxicology?Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Acetaminophen should be a critical reference hepatotoxin for evaluating human-relevant in vitro models.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

J Y Akakpo1 Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
A Ramachandran1 Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
S E Kandel1 Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
H M Ni1 Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
S C Kumer2 Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA.
B H Rumack3 Department of Emergency Medicine and Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
H Jaeschke1 Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.ORCID http://orcid.org/0000-0002-8695-6980
University of Kansas Medical Center · USUniversity of Colorado Denver · US

Funding

Nuclear Receptors in Liver Health and DiseaseP20GM103549 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2012 to 2015
$8.1M
Pilot Grants ProgramP30GM118247 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WEINMAN, STEVEN A · 2016 to 2020
$5.5M
Autophagy and Drug-Induced Liver InjuryR01DK102142 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI DING, WEN-XING, JAESCHKE, HARTMUT W. · 2014 to 2022
$2.7M
Mitochondrial free radical production, biogenesis and their effect on liver regeneration after Acetaminophen (APAP) overdose.F31DK120194 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI AKAKPO, JEPHTE Y. · 2018 to 2020
$98k
NIDDK NIH HHS F31 DK120194NIDDK NIH HHS R01 DK102142NIGMS NIH HHS P20 GM103549NIGMS NIH HHS P30 GM118247
6 · The paper itself

Abstract

Liver injury due to acetaminophen (APAP) overdose is the major cause of acute liver failure in the United States. While treatment with N-acetylcysteine is the current standard of care for APAP overdose, anecdotal evidence suggests that administration of 4-methylpyrazole (4MP) may be beneficial in the clinic. The objective of the current study was to examine the protective effect of 4MP and its mechanism of action. Male C57BL/6J mice were co-treated with 300 mg/kg of APAP and 50 mg/kg of 4MP. The severe liver injury induced by APAP at 6 h as indicated by elevated plasma alanine aminotransferase activities, centrilobular necrosis, and nuclear DNA fragmentation was almost completely eliminated by 4MP. In addition, 4MP largely prevented APAP-induced activation of c-Jun N-terminal kinase (JNK), mitochondrial translocation of phospho-JNK and Bax, and the release of mitochondrial intermembrane proteins. Importantly, 4MP inhibited the generation of APAP protein adducts and formation of APAP-glutathione (GSH) conjugates and attenuated the depletion of the hepatic GSH content. These findings are relevant to humans because 4MP also prevented APAP-induced cell death in primary human hepatocytes. In conclusion, early treatment with 4MP can completely prevent liver injury after APAP overdose by inhibiting cytochrome P450 and preventing generation of the reactive metabolite.

Indexed as

AcetaminophenAnimalsCells, CulturedChemical and Drug Induced Liver InjuryFomepizoleGlutathioneHepatocytesHumansJNK Mitogen-Activated Protein KinasesLiverMaleMice, Inbred C57BLProtective AgentsAcetaminophenFomepizoleGlutathioneJNK Mitogen-Activated Protein KinasesProtective AgentsAcetaminophendrug hepatotoxicitymitochondriaN-acetylcysteinereactive intermediates

Identifiers

PMID29739258
PMCPMC6482816
OpenAlexW2800221622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.